Ex Vivo Expanded Allogeneic γδ T Cells therapy

N/A

Report date: 2022/12/27 12:28:08

Base Information

Drug NameEx Vivo Expanded Allogeneic γδ T Cells therapy
Drug Alias NameEx Vivo Expanded Allogeneic γδ T Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsNeuroblastomaOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEmory University
China Registration ClassN/A

Develop Information

Active CompaniesEmory University
Inactive CompaniesN/A
Active IndicationsNeuroblastomaOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A